Globe Newswire (Thu, 19-Mar 7:21 AM ET)
Globe Newswire (Tue, 17-Mar 5:54 PM ET)
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Globe Newswire (Tue, 24-Feb 8:00 AM ET)
Globe Newswire (Mon, 23-Feb 8:00 AM ET)
Globe Newswire (Wed, 18-Feb 8:00 AM ET)
Registration Momentum Builds Across the Oncology Pipeline
Globe Newswire (Tue, 17-Feb 10:48 AM ET)
Globe Newswire (Fri, 23-Jan 8:11 AM ET)
Acrivon Therapeutics Faces Premarket Drop After Breakthrough Device Designation Announcement
Market Chameleon (Wed, 5-Feb 3:41 AM ET)
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Acrivon Therapeutics trades on the NASDAQ stock market under the symbol ACRV.
As of April 10, 2026, ACRV stock price climbed to $1.56 with 400,693 million shares trading.
ACRV has a beta of 1.32, meaning it tends to be more sensitive to market movements. ACRV has a correlation of 0.05 to the broad based SPY ETF.
ACRV has a market cap of $60.44 million. This is considered a Micro Cap stock.
Last quarter Acrivon Therapeutics reported $0 in Revenue and -$.49 earnings per share. This fell short of revenue expectation by $-541,598 and missed earnings estimates by -$.02.
In the last 3 years, ACRV traded as high as $14.30 and as low as $1.05.
The top ETF exchange traded funds that ACRV belongs to (by Net Assets): VTI, VXF, IWC.
ACRV has underperformed the market in the last year with a return of -3.1%, while the SPY ETF gained +25.2%. In the last 3 month period, ACRV fell short of the market, returning -10.9%, while SPY returned -1.8%. However, in the most recent 2 weeks ACRV has outperformed the stock market by returning +9.9%, while SPY returned +5.3%.
ACRV support price is $1.47 and resistance is $1.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRV shares will trade within this expected range on the day.